Stay updated with breaking news from Egfr Mutations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Jason Porter, MD, highlights the implications of recent data to emerge following the use of EGFR TKIs in the adjuvant setting, the importance of the potential upcoming FDA approval of osimertinib with chemotherapy in EGFR-positive non–small cell lung cancer, and more.
Experts share treatment experiences with osimertinib and afatinib, the potential role of immunotherapy, and ongoing investigations with ADCs and emerging TKIs for patients with uncommon EGFR mutations.
Panelists discuss the intricacies of treating uncommon EGFR mutations, dissecting approved treatment options, considerations for specific mutations, and insights into the evolving drug landscape.
Shared insight into the transformative impact of targeted therapies in lung cancer treatment, from adjuvant therapy breakthroughs to emerging trials, emphasizing the critical role of comprehensive molecular testing.
Shared insight into strategies in genomic testing for lung cancer, emphasizing the importance of comprehensive next-generation sequencing, DNA vs. RNA sequencing, and the evolving role of liquid biopsy.